argenx (ARGX)

• Market cap: $40.5B
• 1 day: 2.36%
• 5 days: 1.01%
• 1 month: 3.30%
• 3 months: 10.65%
• 6 months: 37.59%
• Year to date: 7.50%
• 1 year: 65.27%
• 5 years: 327.75%
• 10 years: 2,798.48%

About: Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.

Employees: 1,148

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

69% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 32

25% more capital invested

Capital invested by funds: $15.1B [Q2] → $19B (+$3.84B) [Q3]

16% more repeat investments, than reductions

Existing positions increased: 133 | Existing positions reduced: 115

6% more funds holding

Funds holding: 331 [Q2] → 350 (+19) [Q3]

6% more call options, than puts

Call options by funds: $292M | Put options by funds: $275M

0% more funds holding in top 10

Funds holding in top 10: 20 [Q2] → 20 (+0) [Q3]

0.66% less ownership

Funds ownership: 59.27% [Q2] → 58.61% (-0.66%) [Q3]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $675 1% upside
• Avg. target: $706 6% upside
• High target: $725 9% upside

9 analyst ratings

• positive: 9 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Douglas Tsao 38% 1-year accuracy 66 / 176 met price target	8% upside $717	Buy Reiterated	14 Jan 2025
Truist Securities Joon Lee 53% 1-year accuracy 23 / 43 met price target	5% upside $700	Buy Reiterated	14 Jan 2025
JMP Securities Jason Butler 45% 1-year accuracy 19 / 42 met price target	4% upside $696	Market Outperform Maintained	14 Jan 2025
Piper Sandler Allison Bratzel 78% 1-year accuracy 7 / 9 met price target	9% upside $725	Overweight Maintained	7 Jan 2025
Wells Fargo Derek Archila 44% 1-year accuracy 16 / 36 met price target	8% upside $723	Overweight Maintained	19 Dec 2024